{"": [82, 223, 0, 224, 540, 0, 541, 893, 0, 894, 1486, 0], "Introduction": [1487, 5844, 0], "Pre-pandemic Sera": [6611, 7237, 0], "COVID-19 Sera": [7238, 8112, 0], "COVID Surveillance Sera": [8113, 8540, 0], "Human Subjects and Biospecimens": [5868, 8540, 1], "Pseudoviruses, Cells, and Key Reagents": [8541, 9064, 0], "ELISA": [9065, 10188, 0], "Saliva Luminex Assay": [10189, 10862, 0], "ROC Curve for RBD IgG ELISA": [10885, 11065, 0], "Association Between Ig Isotype Levels and Days Post Symptom Onset": [11066, 11585, 0], "Statistical Analysis": [10863, 11585, 1], "Materials and Methods": [5845, 11585, 1], "Validation of RBD IgG ELISA": [11595, 12943, 0], "Application of RBD IgG ELISA in Ambulatory Patients": [12944, 13578, 0], "Application of RBD IgG ELISA for Surveillance": [13579, 15350, 0], "Comparative Performance of RBD ELISA to Alternative Serodiagnostic Assays": [15351, 17584, 0], "Association of Antibody Subtypes and Isotypes With Days Post Symptom Onset": [17585, 18973, 0], "Performance of RBD IgG Assay in Different Diagnostic Specimen Types": [18974, 19392, 0], "Results": [11586, 19392, 1], "Discussion": [19393, 29037, 0], "Data Availability Statement": [29038, 29234, 0], "Ethics Statement": [29235, 29460, 0], "Author Contributions": [29461, 30280, 0], "Funding": [30281, 30992, 0], "Author Disclaimer": [30993, 31186, 0], "Conflict of Interest": [31187, 31382, 0], "Publisher's Note": [31383, 31748, 0]}